Kaival Brands' Stock Surges 14% After Winning FDA Lawsuit

Following Bidi Vapor's victory in a court case against the FDA, shares of its distribution company Kaival Brands Innovations Group (NASDAQ: KAVL) rose by 14% to $1.51 in Thursday morning's trading.

In a statement, KAVL announced that the United States Court of Appeals for the Eleventh Circuit ruled in favor of Bidi Vapor with a 2-1 decision and overturned the FDA's order denying the company's non-tobacco flavored BIDI Sticks product's tobacco product application before its launch.

The court stated that the US Food and Drug Administration (FDA) did not take into account the marketing and sales restrictions plan included in Bidi Vapor's comprehensive application. KAVL reported that the court regarded the marketing injunction issued by the FDA against Bidi's device as "arbitrary and capricious".

Statement

This article is compiled from third-party information and is intended only for industry-based exchange and learning.

This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness or accuracy of its content. The translation of this article is only intended for industry exchange and research purposes.

Due to limitations in the level of translation proficiency, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.

In regards to any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions, 2FIRSTS is fully aligned with the Chinese government.

The copyright of the compiled information belongs to the original media and author, if there is any infringement, please contact us for deletion.